![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir
|
|
|
Reported by Jules Levin
Infectious Diseases Society of America, October 3-7, 2018, San Francisco, California  
Christoph Sarrazin1, Jordan J Feld2, Douglas E Dylla3, Sanjeev Arora4, David Victor III5, Yiran B Hu3, Stanley Wang3, Federico J Mensa3, David Wyles6
1JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital, Wiesbaden, Germany; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States; 4University of New Mexico, Albuquerque, New Mexico, United States; 5Houston Methodist Hospital, Houston, Texas, United States;
6Denver Health Medical Center, Denver, Colorado, United States
![1011181](../images%20/101118/101118-1/1011181.gif)
![1011182](../images%20/101118/101118-1/1011182.gif)
![1011183](../images%20/101118/101118-1/1011183.gif)
![1011184](../images%20/101118/101118-1/1011184.gif)
![1011185](../images%20/101118/101118-1/1011185.gif)
![1011186](../images%20/101118/101118-1/1011186.gif)
![1011187](../images%20/101118/101118-1/1011187.gif)
![1011188](../images%20/101118/101118-1/1011188.gif)
![1011189](../images%20/101118/101118-1/1011189.gif)
![10111810](../images%20/101118/101118-1/10111810.gif)
![10111811](../images%20/101118/101118-1/10111811.gif)
![10111812](../images%20/101118/101118-1/10111812.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|